UNH

Strategic Conclusion

• Recommendation: Buy
• Why? UNH is trading just above its 200-day SMA after a sharp pullback, with RSI at 30.2 signaling oversold conditions. The 50-day SMA remains above the 200-day SMA, preserving the medium-term uptrend. Analyst consensus is strongly bullish (1.97 mean, 27 buy ratings), and the P/E of 23.9 is reasonable for a healthcare giant with stable cash flows. The negative MACD is the main short-term risk, but the risk/reward at this level favors accumulation.
• Ideal profile: Long-term investor with 6–12 month horizon; also suitable for swing traders looking for an oversold bounce near support.
• Price range: Entry zone $370–$378; first target $406 (SMA50); second target $430–$440. Stop-loss below $350 (below SMA200).
• Practical action: Buy in tranches near current levels. Add on a dip toward $355–$360 if it tests the 200-day SMA. Reduce or exit if price closes below $350.

1. Recent Price & Momentum

• Current price $375.26 is 18.7% below the 52-week high of $461.62 and 46.6% above the low of $255.97 — roughly in the middle of the range but closer to the lower half after recent selling.
• Price is below the 50-day SMA ($406.43) but above the 200-day SMA ($353.82), indicating a pullback within a longer-term uptrend.
• Short-term scenario: If $353–$355 holds, a rebound toward $406 is likely. A break below $353 would open the door to $330–$340.

2. Valuation (P/E)

• P/E TTM of 23.90 is above the broad market average but within normal range for a large-cap managed care company with predictable earnings and dividend growth.
• The multiple suggests the market is pricing in moderate growth, not aggressive expansion. After the recent decline, valuation is more attractive than at the 52-week high.
• Dividend yield of 1.37% adds a modest income cushion while waiting for recovery.

3. Technical Analysis

• SMA50 ($406.43) > SMA200 ($353.82): golden-cross structure, medium-term uptrend intact.
• RSI(14) at 30.2: near oversold, historically a zone where bounces occur.
• MACD: -6.77, below signal -5.26, with negative histogram — bearish momentum still in control.
• Technical score: 80/100 → BUY, driven by the golden-cross structure and analyst support, but momentum is the weak spot.

4. Analyst Consensus

• Mean rating 1.97/5 with 27 buy, 7 hold, 0 sell — Wall Street is clearly bullish.
• This aligns with the technical score and the long-term trend, but diverges from the short-term MACD signal. The consensus supports buying weakness rather than chasing strength.